In this week’s news: Envelope-only vaccine protects in monkeys, capsid is a potential new therapeutic target, combination drugs work better in preventing MTCT, open access advocates are not happy with the UK report recommending more open access
- Study finds vaccine with envelope alone can protect monkeys from SIV challenge – the vaccine consisted of two replication-defective vectors carrying the SIV envelope gene, eliciting both cellular and humoral immune responses, which were sufficiently robust to give 60% efficacy in monkeys challenged by a heterologous SIV variant
- New drug-screening method yields long-sought anti-HIV compounds – the search identified two small molecule compounds that specifically bind to HIV nucleocapsid protein and disrupt viral replication
- Drug combo can block mother-to-infant HIV transmission, study suggests – for infants born to non-treated HIV-positive mothers, using a two- or three-drug combination in the first 48 hours after birth is more effective at blocking intrapartum transmission than AZT alone
- Last week we covered the Finch Report, which suggested that UK government should move toward making all publicly-funded research openly available. The report received mixed, if not harshly critical, reviews from open-access proponents because it focused on gold open access without highlighting the cheaper green model of open access:
If you are a member, please log in to post new comment. If you would like to become a member please create a new profile here.